A key objective of the Male Hypogonadism Report is to understand the
market and pipeline status of the drugs around the Male Hypogonadism to
explore the generic development opportunities, licensing opportunities
and to gain competitive advantage on designing pipeline strategies. The
Report provides the historical and forecasted sales of the drugs till
2018.

The Report gives insights into patents providing the patent protection
data and marketing exclusivity of all the drugs across the Male
Hypogonadism, while the leading brands, companies and chemicals are
considered thoroughly.

The Report also provides details on the Global API Manufacturers across
the globe covering Drug Master Filings of US, Europe and API
Manufacturers in Asia specifically China and India.